This trial is withdrawn!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Fibrosis, Renal Failure or Hepatorenal Syndrome
and you are
between 18 and 80
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The aim of this study is to evaluate the treatment with midodrine, octreotide and albumin during 12 weeks in patients with hepatorenal syndrome. Fifteen patients will be enrolled and followed during 16 weeks. The effects on renal function will be evaluated 12 and 16 weeks after the beginning of the treatment by isotopic evidence and biochemist determinations. Also it will be evaluated arterial pressure and determination of vasoactive hormones (plasma renin, aldosterone and norepinephrine).

Provided treatments

  • Drug: Albumin
  • Drug: Midodrine
  • Drug: Octreotide

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01587222. The sponsor of the trial is Anna Cruceta and it is looking for 0 volunteers for the current phase.
Official trial title: